Nav1.8 is a tetrodotoxin-resistant voltage-gated sodium-channel alpha subunit encoded by SCN10A. It is strongly associated with peripheral nociceptor excitability and sustained pain signaling, especially under inflammatory and neuropathic conditions.[1][2][3] Relative to several other Nav channels, Nav1.8 contributes disproportionately to repetitive firing in C-fiber pathways, making it a persistent focus for non-opioid analgesic discovery.[2:1][4]
Although mainly studied in pain biology, SCN10A/Nav1.8 has broader translational relevance through links to autonomic and cardiac conduction phenotypes and through overlap with peripheral-neuropathy burdens in neurodegenerative cohorts.[5][6]
Nav1.8 follows the canonical Nav alpha-subunit topology (DI-DIV, each with S1-S6 helices), but functionally is distinguished by tetrodotoxin resistance and kinetic properties that support ongoing spiking during prolonged depolarization.[1:1][2:2]
Important operational features include:
In peripheral sensory neurons, Nav1.8 supports:
Mouse genetics and pharmacologic models repeatedly show that reducing Nav1.8 function can blunt specific pain behaviors, especially in chronic and inflammatory settings.[2:5][3:2][7]
Nav1.8 is implicated across chronic pain domains, including inflammatory pain, neuropathic pain phenotypes, and inherited pain-channel syndromes where SCN10A variants co-occur with other sodium-channel risk backgrounds.[3:3][7:1][8]
Independent of nociception, common and rare SCN10A variants have been associated with cardiac conduction traits and arrhythmia susceptibility in population and mechanistic studies.[5:1][6:1] This dual-domain biology is a key translational constraint when developing systemic Nav1.8 inhibitors.
For neurodegeneration programs, Nav1.8 is best framed as a symptomatic-mechanistic target (pain and sensory burden) rather than a core disease-modifying target in primary proteinopathy mechanisms. It remains clinically important for quality-of-life outcomes and multimorbidity management in long-duration disease trajectories.[4:2][8:1]
Interest in Nav1.8 has accelerated with recent highly selective inhibitor programs, including human-neuron translational studies on suzetrigine-like pharmacology.[7:2] Core strategic goals are:
As with Nav1.7, target validity is high in pain circuitry; the main bottleneck is durable clinical efficacy with acceptable safety across heterogeneous patient populations.[4:4][8:3]
Within the NeuroWiki rubric framework:
This split supports using Nav1.8 in symptom-control pathways while avoiding over-claiming direct neuroprotective effect.
Akopian AN et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nature Neuroscience. 1999. ↩︎ ↩︎
Zimmermann K et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature. 2007. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Han C et al. Sodium channel Nav1.8: Emerging links to human disease. Neurology. 2016. ↩︎ ↩︎ ↩︎ ↩︎
Xie YF et al. Nav1.8 and Chronic Pain: From Laboratory Animals to Clinical Patients. Biomolecules. 2025. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chambers JC et al. Genetic variation in SCN10A influences cardiac conduction. Nature Genetics. 2010. ↩︎ ↩︎
Macri V et al. Common Coding Variants in SCN10A Are Associated With the Nav1.8 Late Current and Cardiac Conduction. Circulation: Genomic and Precision Medicine. 2018. ↩︎ ↩︎
Stewart RG et al. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine. Proceedings of the National Academy of Sciences of the United States of America. 2025. ↩︎ ↩︎ ↩︎ ↩︎
Xue Y et al. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models. Neuroscience Letters. 2021. ↩︎ ↩︎ ↩︎ ↩︎